EPHA2 PAT66G9AT Antibody
Description
Research Applications
The EPHA2 PAT66G9AT Antibody is validated for multiple experimental techniques:
2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
-
Role: Detects EPHA2 in solution-phase assays.
-
Use Case: Quantifies EPHA2 expression levels in cell lysates or serum.
2.2. Western Blot (WB)
-
Role: Identifies EPHA2 in denatured protein samples.
-
Use Case: Analyzes EPHA2 expression in tumor tissues or cell lines.
2.3. Flow Cytometry
-
Role: Detects cell surface EPHA2 expression.
-
Use Case: Profiles EPHA2-positive cancer cells (e.g., epithelial carcinomas).
2.4. Immunocytochemistry/Immunofluorescence (ICC/IF)
-
Role: Localizes EPHA2 within cells.
-
Use Case: Visualizes EPHA2 distribution in fixed cell cultures or tissue sections.
Sources:
Cross-Reactivity and Specificity
-
Specificity: The antibody binds exclusively to human EPHA2 without cross-reacting with non-target antigens (e.g., BSA) or related receptors (e.g., EPHA4).
-
Validation: Confirmed via competition assays and immunoprecipitation studies.
Source:
Comparative Context
While the EPHA2 PAT66G9AT Antibody is distinct, other EPHA2-targeting antibodies (e.g., 1C1, IgG25, IgG28) have demonstrated therapeutic potential in preclinical models. For example:
-
1C1-mcMMAF: An antibody-drug conjugate inhibiting EPHA2-expressing tumors via receptor internalization and degradation .
-
IgG25/IgG28: Agonistic and antagonistic antibodies, respectively, showing anti-tumor efficacy in pancreatic cancer models .
Sources:
Product Specs
Product Science Overview
EPHA2 is involved in numerous cellular processes and has been implicated in the progression of various cancers. It is known to influence cell morphology and motility by interacting with its ephrin ligands, which are membrane-bound proteins. The binding of ephrin ligands to EPHA2 triggers bidirectional signaling, affecting both the receptor-expressing and ligand-expressing cells.
The PAT66G9AT is a mouse monoclonal antibody specifically designed to target the human EPHA2 receptor. This antibody is produced by hybridizing mouse F0 myeloma cells with spleen cells from BALB/c mice that have been immunized with human EPHA2 . The resulting hybridoma cells produce the PAT66G9AT antibody, which can be used in various applications such as Western Blotting (WB), Immunocytochemistry (ICC), and Immunofluorescence (IF) .
The PAT66G9AT antibody is widely used in research to study the expression and function of EPHA2 in different cell types and tissues. It is particularly valuable in cancer research, where EPHA2 is often overexpressed and associated with tumor progression and metastasis. By using this antibody, researchers can investigate the role of EPHA2 in cancer and potentially develop targeted therapies.
